|Mr. John K. Celebi||Pres, CEO & Director||532.63k||N/A||1972|
|Dr. Robert Hamilton Pierce||Chief Scientific Officer||488.03k||N/A||1964|
|Ms. Anupama Hoey M.B.A., M.S.||Chief Bus. Officer||121.65k||N/A||1971|
|Ms. Erin Colgan||Sr. VP of Fin. & Admin.||N/A||N/A||1981|
|Dr. Steven A. Fuller||Chief Biopharmaceuticals Devel. Officer||N/A||N/A||N/A|
|Ms. Lora Pike||VP of Investor Relations & Communications||N/A||N/A||N/A|
|Dr. Marie-Louise Fjallskog M.D., Ph.D.||Chief Medical Officer||N/A||N/A||1964|
Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland.
Sensei Biotherapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.